Research Article
Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration
Table 1
Demographic and ocular characteristics of 144 patients in two regimens.
| | Characteristics | Overall
() | Regimen A
() | Regimen B
() | |
| | Age (years) | | | | | | Mean (SD) | 68.8 (8.6) | 67.7 (9.1) | 70.0 (8.0) |
0.111 | | Range | | | | | Age group (%) | | | | | | 50–59 years | 26 (18.1) | 17 (23.0) | 9 (12.9) |
0.231 | | 60–69 years | 43 (29.9) | 22 (29.7) | 21 (30.0) | | 70–79 years | 62 (43.1) | 31 (41.9) | 31 (44.3) | | ≥80 years | 13 ( 9.0) | 4 (5.4) | 9 (12.9) | | Gender (%) | | | | | | Male | 95 (66.0) | 47 (63.5) | 48 (68.6) |
0.522 | | Female | 49 (34.0) | 27 (36.5) | 22 (31.4) | | Smoking* (%) | | | | | | No | 77 (53.8) | 40 (54.8) | 37 (52.9) |
0.816 | | Yes | 66 (46.2) | 33 (45.2) | 33 (47.1) | | VA score (letters) Mean ± SD | | | | | | Baseline | | | |
0.099 | | 6 months | | | |
0.954 | | Lesion type* (%) | | | | | | Occult only | 57 (44.9) | 27 (42.9) | 30 (46.9) |
0.467 | | Minimally classic | 21 (16.5) | 13 (20.6) | 8 (12.5) | Predominantly
classic | 49 (38.6) | 23 (36.5) | 26 (40.6) | | Duration of neovascular AMD* (%) | | | | | | <1 month | 5 (3.8) | 0 (0.0) | 5 (7.6) |
0.067 | | 1–6.9 months | 70 (53.0) | 40 (60.6) | 30 (45.5) | | 7–12 months | 26 (19.7) | 11 (16.7) | 15 (22.7) | | >12 months | 31 (23.5) | 15 (22.7) | 16 (24.2) | | CRT (m)* median | | | | | | Baseline | 344.5 | 349.0 | 344.5 | 0.346 | | 6 months | 229.0 | 227.5 | 230.0 | 0.667 |
|
|
AMD: age-related macular degeneration; CRT: central retinal thickness; SD: standard deviation; VA: visual acuity.
*Variable that had missing values.
|
